{"id":"long-acting-fsh-and-gnrh-antagonist","safety":{"commonSideEffects":[{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Abdominal pain/discomfort"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The FSH component stimulates follicle development in the ovaries, while the GnRH antagonist suppresses endogenous GnRH signaling to prevent premature LH surge and control the timing of ovulation. This dual mechanism allows sustained hormonal control over multiple days or weeks with a single administration, improving convenience in assisted reproductive therapy.","oneSentence":"This drug combines long-acting FSH (follicle-stimulating hormone) activity with GnRH antagonism to modulate reproductive hormone signaling for extended periods.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:52:53.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Controlled ovarian hyperstimulation in assisted reproductive technology (ART) / in vitro fertilization (IVF)"}]},"trialDetails":[{"nctId":"NCT01206803","phase":"","title":"Ovarian Response Prediction in In Vitro Fertilization (IVF) Patients","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2010-09","conditions":"Infertility, Subfertility","enrollment":294},{"nctId":"NCT01633580","phase":"PHASE4","title":"D2 Versus D4 Corifollitropin Alfa in GnRH Antagonists","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2011-12","conditions":"Infertility","enrollment":67},{"nctId":"NCT02070198","phase":"PHASE4","title":"Long Acting FSH Plus Antagonist Versus Daily FSH Plus Antagonist Versus Short Agonist Protocol in Poor Responders Undergoing IVF","status":"UNKNOWN","sponsor":"Bioroma","startDate":"2013-12","conditions":"Female Infertility, Poor Responder","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Long acting FSH and GnRH antagonist","genericName":"Long acting FSH and GnRH antagonist","companyName":"Bioroma","companyId":"bioroma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug combines long-acting FSH (follicle-stimulating hormone) activity with GnRH antagonism to modulate reproductive hormone signaling for extended periods. Used for Controlled ovarian hyperstimulation in assisted reproductive technology (ART), Male infertility due to hypogonadism or spermatogenesis disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}